A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)

Simon I Noble,1,2* Annmarie Nelson,2 David Fitzmaurice,3 Marie-Jet Bekkers,4 Jessica Baillie,5 Stephanie Sivell,2 Joanna Canham,1 Joanna D Smith,1 Angela Casbard,1 Ander Cohen,6 David Cohen,7 Jessica Evans,1 Kate Fletcher,8 Miriam Johnson,9 Anthony Maraveyas,10 Hayley Prout2 and Kerenza Hood4

1Wales Cancer Trials Unit, School of Medicine, Cardiff University, Cardiff, UK
2Marie Curie Palliative Care Research Centre, Cardiff University, Cardiff, UK
3Department of Primary Care Clinical Sciences, University of Birmingham, Edgbaston, UK
4South East Wales Trials Unit, Cardiff University, Cardiff, UK
5School of Healthcare Science, Cardiff University, Cardiff, UK
6Department of Surgery and Vascular Medicine, King’s College Hospital, London, UK
7Faculty of Health, Sport and Science, University of South Wales, Pontypridd, UK
8Birmingham Primary Care Clinical Research and Trials Unit, University of Birmingham, Edgbaston, UK
9St Catherine’s Hospice, Scarborough, UK
10Department of Academic Oncology, University of Hull, Hull, UK

*Corresponding author
Declared competing interests of authors: Dr Noble has declared he reports grants from LEO Pharma during the conduct of the study; personal fees from LEO Pharma, grants from Pfizer Inc., personal fees from Bristol-Myers Squibb and personal fees from Boehringer Ingelheim, outside the submitted work. Professor Fitzmaurice has declared he is on the Health Technology Assessment Commissioning Board and Professor Hood is on the Clinical Trials Unit Standing Advisory Committee. Dr Cohen reports personal fees from Cardiff University during the conduct of the study; personal fees from Boehringer Ingelheim, grants and personal fees from Daiichi Sankyo, grants and personal fees from Bristol-Myers Squibb, personal fees from Johnson & Johnson, grants and personal fees from Pfizer Inc., personal fees from Portola Pharmaceuticals Inc., personal fees from Sanofi, personal fees from XO1 Ltd, and personal fees from Janssen Pharmaceutical, outside the submitted work. Dr Johnson reports grants from the National Institute of Health Research during the conduct of the study, and other grants from Mayne Pharma outside of the submitted work.

Published October 2015
DOI: 10.3310/hta19830

Scientific summary

The ALICAT feasibility study
Health Technology Assessment 2015; Vol. 19: No. 83
DOI: 10.3310/hta19830

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Venous thromboembolism (VTE) is common in cancer patients, affecting up to 20% of cancer patients during their lifetime. The standard treatment of VTE is well established, consisting of 5 days’ anticoagulation treatment with low-molecular-weight heparin (LMWH), followed by 3–6 months of warfarin. However, the management of cancer-associated thrombosis (CAT) presents several challenges with a higher rate of both re-thrombosis and bleeding among cancer patients compared with those with non-malignant disease. A strong evidence base and international guidelines recommend 6 months’ anticoagulation treatment with LMWH. Current data recommend LMWH for anticoagulation as far as 6 months, yet guidelines recommend anticoagulation treatment beyond 6 months in patients who have ongoing or active cancer. This expert consensus recommendation, based on the theory that the presence of active cancer will confer an ongoing risk for VTE, has not been evaluated in a clinical study. A randomised controlled trial (RCT) to evaluate whether or not patients with ongoing cancer and VTE should be anticoagulated for longer than 6 months is clearly needed. However, there are concerns that such a study would be challenging to recruit to, since many clinicians already treat patients with anticoagulants longer than 6 months as standard practice. The ALICAT (Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis) trial was undertaken to establish the feasibility of progressing to a full RCT to identify the most clinically and cost-effective length of anticoagulation with LMWH in the treatment of CAT.

Study aims

The aims of the study were:

• to identify practicalities of conducting a full RCT with regard to recruitment, retention and outcome measurement
• to explore the barriers to progressing to a full RCT.

Primary outcomes

The primary outcomes of the study were:

i. number of eligible patients over 12 months
ii. number of recruited patients over 12 months (target recruitment rate of 30% of eligible patients)
iii. proportion of randomised participants with recurrent VTEs during follow-up.

Secondary outcomes

The secondary outcomes of the study were:

i. completion of a trial protocol
ii. costs
iii. quality of life
iv. symptom assessment
v. attitudes of clinicians and patients.
Methods/design

The ALICAT trial was a randomised, multicentre, feasibility mixed-methods study with three components: (1) a RCT, (2) a nested qualitative study and (3) a UK survey.

Randomised controlled trial

Patients with ongoing active or metastatic cancer who had received 6 months of LMWH for CAT, were invited to participate. Patients were randomised to continue LMWH for a further 6 months or to stop (usual licensed practice). Patients were reviewed at 3 months and 6 months from randomisation, and evaluated for recurrent VTE and bleeding. They completed quality-of-life, symptom and health resource usage questionnaires.

In order to identify the best clinical environment to recruit from, we designated three clinical settings as recruitment sites: oncology outpatients, haematology outpatients and primary care. This was an open-label, non-placebo controlled trial with 1 : 1 randomisation.

Nested qualitative study

Patients who declined to participate in the study were invited to participate in a semistructured qualitative interview. Reasons for declining participation were explored.

Likewise, patients agreeing to randomisation were interviewed about their experiences of participating in the study including drivers for compliance and retention in the trial.

Focus groups were organised with clinicians from three clinical settings (oncology, haematology and primary care) to explore the following topics:

- attitudes to recruiting to the study in terms of recruitment, equipoise and acceptability of the intervention, and outcome measures
- their experiences of, and attitudes to, prescribing LMWH, including whether or not they would extend treatment past 6 months.

UK survey

This component of the study comprised telephone and web-based surveys to identify the models of care in existence for CAT along with identifying variations in patient pathways.

Results

Randomised controlled trial

There were significant delays in opening recruitment sites, which, in part, reflected the complexity of the study, with the settings being across primary care, secondary care and under English and Welsh research processes. Key areas of delay included agreement of contracts between organisations, internal approval systems for each recruitment site and repetition of approval requirements between two research organisations.

On reviewing set-up processes and projected site opening times, it was agreed to close the study to primary care and focus on opening oncology and haematology sites. During the intended recruitment period, only the oncology sites were opened. The first haematology site opened just as the decision to close the overarching study was made.

Over a 6-month period, 5 out of 32 eligible participants consented to randomisation. This number was significantly below the target of 15 out of 62. It was therefore concluded that it was not feasible to progress to a full RCT.
Nested qualitative study

Eight patients who had declined randomisation consented to a qualitative interview. Patients reported they had been given sufficient information and opportunity for questions about the study. They also understood the purposes of the study. However, their prior experiences of VTE had, in part, consolidated their attitudes to anticoagulation, be it to continue or to stop.

For those diagnosed with incidental or asymptomatic pulmonary emboli, there was a desire to stop the injections as soon as possible. As their diagnosis was not associated with distressing symptoms, they did not see any strong reason to continue. They did not want to enter the study and risk being randomised to continue LMWH.

Patients with symptomatic VTE often found the experience distressing and therefore associated the LMWH injections with making them better. Many of them feared a recurrence of VTE and as such were unwilling to stop the treatment. Likewise, they did not want to risk randomisation to stop LMWH.

Focus groups were conducted in primary care, haematology and oncology departments. Clinicians readily acknowledged the gap in clinical data and the rationale for the study. For many, however, anticoagulation beyond 6 months had already become custom and practice, and they were unwilling to recruit patients whom they believed were at risk of ongoing VTE. Clinicians did not believe the study had equipoise based on their clinical experience. Some suggested they would be willing to recruit certain subgroups of patients, thereby generating a biased sample. Some also considered whether or not a study that continued LMWH at a lower dose instead of stopping completely may be better.

UK survey

Patient pathway modelling suggested that there is a broad heterogeneity of practice with respect to CAT management and co-ordination with no consensus on which specialty should best manage such cases.

Conclusion

At the current time it is not feasible to recruit sufficient patients with advanced cancer and VTE to a RCT exploring the most effective way to manage CAT after 6 months’ anticoagulation therapy with LMWH.

Several barriers have been identified. The process-related delays are not insurmountable, but allowing a longer run-in period would provide a greater likelihood of opening sites on time.

However, even with the most efficient processes in place, it appears that patients themselves are unwilling to participate in such a study since their experience of the index VTE event impacts considerably on how they view the necessity of LMWH. Clinicians, likewise, do not consider such a study holds true equipoise while readily identifying this view is largely based on intuition and less so hard data.

Study registration

This study is registered as clinical trials.gov number NCT01817257 and International Standard Randomised Controlled Trial Number (ISRCTN) 37913976.

Funding details

Funding for the ALICAT trial was provided by the Health Technology Assessment programme (10/145/01) in response to a themed funding call. The study was designed in accordance with the initial funding brief and feedback from the review process.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 10/145/01. The contractual start date was in March 2013. The draft report began editorial review in February 2015 and was accepted for publication in August 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2015. This work was produced by Noble et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk